Introduction
============

Cellular mediated immune responses to brucellosis drive a broad range of manifestations of the disease that vary from subclinical infection (more common with *Brucella abortus*) to undulant fever, to focal pyogenic infection, to chronic fatigue syndrome-like illness (Yingst and Hoover, [@B25]; Yang et al., [@B24]). However, the molecular mechanisms that determine the variable manifestations of *Brucella* infection remain to be elucidated. Information on acquired immunity to human brucellosis has been accumulated through observational studies of naturally infected hosts (cattle, goats), experimental models (mice), and observations of human disease. Three predominant *Brucella* species are seen frequently in human infections: *B. melitensis*, *B. abortus*, and *B. suis*. Of these three species, *B. melitensis* infections are most commonly seen in humans and seem to be the most pathogenic (Pappas et al., [@B16]). In the United States, domesticated cattle, which are potential reservoirs for the organism, are vaccinated against *B. abortus* (RB51 or S19); elsewhere (in the Middle East and Latin America), goats and sheep may be vaccinated with Rev-1, an attenuated strain of *B. melitensis*. Currently available veterinary vaccines are comprised of live-attenuated organisms but are unacceptable in humans because they cause clinical disease (Kinikli et al., [@B11]; Durward et al., [@B7]).

Brucellosis can occur in several forms: acute/subacute (associated with positive blood cultures, high titer agglutination serologies), focal (blood culture negative, serologically variable, and positive local site culture), and chronic (blood culture negative, serologically variable but often negative, sometimes bone marrow culture positive, often diagnosed clinically in response to therapy; Jimenez de Bagues et al., [@B10]). However, it is currently unknown what causes some individuals to have the acute form and some to progress and develop chronic disease. As hypothesized in this review and elsewhere, it seems probable that immunogenetics of cell-mediated immune responses to *Brucella* protein antigens determines clinical manifestations and outcome. Sometimes, despite treatment for brucellosis, there are still some bacterial foci that may persist despite antibiotics or *Brucella* DNAemia may persist, presumably because of deficient T cell activation of infected macrophage/dendritic cells (DCs; Vrioni et al., [@B23]). Additional mechanisms may also include altered innate immune responses determined by the pathogenetic properties of the bacteria themselves. There have been studies demonstrating that *Brucella* epitopes can include those recognized by peptide-specific CD8+ T cells associated with protective responses at least in a mouse model (Durward et al., [@B7]). While there has been an experimental interferon-gamma release assay developed for bovine brucellosis, there has not been one developed for human infection to differentiate immune responses associated with different forms of brucellosis, to definitely diagnose previous exposure, or identify targets of protective immunity. Understanding the precise molecular targets (protein, peptidic epitope) of T cell-mediated immune responses has the promise to translate to further investigations into new vaccine and diagnostic *Brucella* T cell epitopes, and their role in specific T cell-mediated responses.

T Cell Cytokine Responses to *Brucella* Infection
=================================================

Infections may occur after ingestion or inhalation of *Brucellae* that penetrate mucosal surface such as the upper respiratory or gastrointestinal mucosa via lymphoid cells. Once the bacteria are phagocytosed by macrophages, DCs (Billard et al., [@B3]), and other antigen presenting cells (APCs), approximately 40--50% of the bacteria resist digestion within these cells. *B. abortus* and *B. melitensis* that have smooth LPS (with intact O-antigen chain) are able to survive better intracellularly than *B. canis* that has rough LPS (lacks O-antigen side chain; Vrioni et al., [@B23]). *Brucella* spp. LPS is also composed of longer carbon chains (C28) as apposed to the usual 12--16 carbons in the LPS from *Enterobacteriaceae*. In addition, *Brucella* spp. produce proteins (e.g., Vi antigen), which create a capsule around the LPS, therefore limiting it to have contact with TLR4 receptors (Lapaque et al., [@B12]; Tsolis et al., [@B22]). In addition, the domain for the flagellin protein in *Brucella* spp. does not stimulate TLR5 receptors, and is another way for the bacteria to evade the immune system during early infection (Tsolis et al., [@B22]). These areas are conserved in all *Brucella* spp. and to others in the same family to evade detection by the immune system during the infection and possibly allowing the bacteria to persist in the reticuloendothelial system (Tsolis et al., [@B22]; Barquero-Calvo et al., [@B2]).

After initial encounter with *Brucella* antigens, APCs produce interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and gamma-interferon (IFN-γ) initiating innate immune responses (including natural killer cells) that may limit the initial spread of organisms. Infected APC in which organisms residing within unactivated phagolysosomes are likely to present some subset of peptidic *Brucella* antigens (hitherto unknown) to CD4+ and CD8+ cells, and thus inducing a TH~1~ response associated with IFN-γ release. The functional consequences of antigen-specific IFN-γ release is unclear but does not lead to elimination of organisms during active, symptomatic infection and likely results in clinical symptomatology (i.e., fever, sweating, weight loss). Clonal T cell expansion is initiated with production of interleukin-2 (IL-2) and interleukin-12 (IL-12), which initiates a CD8+ cytotoxic response on *Brucella*-infected cells. Infected macrophages produce IL-12 and IFN-γ which regulate antigen presentation and may contribute to the limitation of intracellular bacterial replication through unknown mechanisms (Akbulut et al., [@B1]). Data also suggest that *Brucella* spp. also modify the initial immune response once phagocytosed into APCs. To survive within APCs, *Brucella* use certain gene products to subvert certain phagocyte intracellular processes, particularly phagosome--lysosome fusion which would be associated with bacterial killing. One way that the organism survives within APCs is through *Brucella*-containing vacuoles (BCVs), which the organism secretes *Sar1*, a critical protein which allows the organism to replicate within these vacuoles (Celli et al., [@B5]). CD64, also known as FcγRI, is a macrophage-expressed gene whose expression is down-regulated in *B. melitensis* infections (Lapaque et al., [@B12]), reflecting the reduction of antigen processing in *Brucella-*infected APCs and possibly inhibiting the killing of infected cells initiated by CD4+ and CD8+ T cells. This mechanism may be important for decreasing superoxide and reactive nitrogen compounds as another pathogen-associated localized immunosuppression. Other gene products such as cystatin C, serpina3c, and Gas2 (natural peptidase inhibitors) appear to alter macrophage chemotaxis, cell migration, and proliferation, which may further allow *Brucella* to avoid immune surveillance and lead to enhanced multiplication (Lapaque et al., [@B12]). Decreased transcription of Cyp4a10 is thought to be associated with the reduction of oxidative stress that creates an environment conducive to bacterial proliferation. *Prkca* is another macrophage-associated gene potentially modulated during *Brucella* infection, who functions includes regulating phagosome--lysosome fusion and intracellular vesicle and reactive oxygen species (ROS) generation. *Prkca* expression is dramatically reduced in *Brucella*-infected macrophages, and interestingly, has been shown to be regulated by other intracellular pathogens such as *Salmonella*, *Leishmania*, and *Legionella*. All these mechanisms contribute to allowing *Brucellae* to survive within the intracellular environment, and evade not only the innate immunity, but CD4+- and CD8+-mediated host cell killing (Covert et al., [@B6]).

Alteration of T cell function may be key to explaining the clinico-pathological manifestations of chronic or relapsing brucellosis. Specifically, a decreased TH~1~ cytokine response by APCs (with decreased activation of cytotoxic T cells via IFN-γ, IL-12, and possibly IL-17 (Pasquevich et al., [@B17]), and toward a TH~2~ response (which decreases phagocyte function and reduced cytotoxic response via IL-4, IL-5, and IL-10; Jimenez de Bagues et al., [@B10]). These infected cells fail to produce IFN-γ, and decrease clonal expansion of *Brucella*-specific CD4+ T cells. Subsequently, *Brucella*-specific CD8+ T cells would not initiate destruction of infected cells by perforin and granzyme injection (cell lysis) or through stimulation of FAS ligand (cellular apoptosis; Yingst and Hoover, [@B25]; Skendros et al., [@B20]). Based on these considerations, the unusual and diverse manifestations of chronic and relapsing brucellosis could be related to several potential immunopathogenic mechanisms: an ineffective CD4+ effector response, a down-regulated CD8+ T cell response or a continued, established TH~2~ response, each of which could result in an incomplete resolution of the infection (Giambartolomei et al., [@B9]). In comparing cytokine responses in patients with acute and chronic brucellosis, before and after treatment, Akbulut et al. ([@B1]) found that in chronic brucellosis, both the absolute number of CD4+ cells and the quantitative secretion of IFN-γ were reduced. Rafiei et al. ([@B18]) confirmed these results, and further demonstrated that IL-13 is increased in chronic brucellosis, further demonstrating the initial association of TH~1~ cytokine responses with acute brucellosis illness, which gradually becomes TH~2~ cytokine dominant. These observations suggest that once acute brucellosis has resolved, that both the number of CD4+ cells and CD4+ functional response is reduced. Whether antigen-specific memory CD4+ cells are produced during acute or chronic brucellosis remains to be determined (Moreno-Lafont et al., [@B15]; Akbulut et al., [@B1]; Kinikli et al., [@B11]). Recently Elfaki and Al-Hokail observed that mice deficient in β2-microglobulin produced an impaired CD8+ response associated with increased *Brucella* bacterial load and decreased clearance (Moreno-Lafont et al., [@B15]; Elfaki and Al-Hokail, [@B8]). Extrapolating such results to human disease, chronic or relapsing brucellosis might be explained in that CD69 expression on both CD4+ T cells and CD8+ T cells are significantly decreased in this patient subset. Further experimentation indicates that there is an unknown individual effect on the immune system after an episode of acute brucellosis, and therefore one develop chronic and relapsing brucellosis.

*Brucella* Proteins Recognized in Human Immune Responses
========================================================

Epitopes are the molecular subset of any macromolecule recognized by antibodies, B cells, T cells, and NK cells. T cells recognize peptides generally of 8--20 amino acids bound to MHC molecules (HLA Class I associated with CD8+ T cells; HLA Class II associated with CD4+ T cells) presented on the surface of a B cell, macrophage or dendritic cell (Yang et al., [@B24]). Non-classical MHC molecules also present non-peptidic epitopes such as glycolipids to non-restricted lymphocytes, particularly NK cells. There are only a few studies in the literature that have demonstrated either a humoral or cellular response to *Brucella* epitopes. The epitopes of greatest interest to date include Bp26 (a periplasmic protein), Trigger Factor (a chaperone protein; Yang et al., [@B24]), and the outer membrane lipoproteins such as Omp 10, 16, and 19 (Tibor et al., [@B21]). Interestingly, these antigens, especially the outer membrane lipoproteins, appear to be potent in inducing cytokine responses from memory T cells. In contrast, *Brucella* LPS and *Brucella* DNA do not elicit intense immune responses (Giambartolomei et al., [@B9]; Vrioni et al., [@B23]). Previous vaccine studies in mice have used some of these outer membrane epitopes (Pasquevich et al., [@B17]) as well as certain enzymes such as Cu--Zn superoxide dismutase (Singha et al., [@B19]). Yet, these were not demonstrated to offer protection for humans or T cell cytokine release assays to prove their efficacy.

These antigens have been identified in both *B. melitensis* and *B. abortus*. Bp26 and Trigger Factor have been shown to be recognized by the immune system (Yang et al., [@B24]), yet with a reduced activation in patients with chronic/relapsing brucellosis. Recently, Liang et al. ([@B13], [@B14]) reported comprehensive systems biology analyses of human antibody responses in acute *B. melitensis* brucellosis in Peru. A collection of sera isolated from individuals from one of the following groups was used to probe large scale *B. melitensis* protein microarrays including a ∼1400 proteins array and 3300 proteins array representing nearly the entire encoded proteome: *Brucella* blood culture positive, blood culture negative with positive Rose Bengal, blood culture negative with negative Rose Bengal, and two naïve groups (from both American and Peruvian individuals.) Sets of proteins that differentiated acutely infected from uninfected patient groups were identified that were recognized by patient IgG responses. These *Brucella* protein epitopes were then further separated by the patient groups which recognized them, as some were only recognized by culture positive or culture negative patients/Rose Bengal positive patients compared to naïve patients (Table [1](#T1){ref-type="table"}), others cross react in both the culture positive patients and the naïve patients (Table [2](#T2){ref-type="table"}) and some antigens produced a positive response in the culture positive group but not the culture negative group/Rose Bengal positive group (Table [3](#T3){ref-type="table"}). This broad spectrum of antibody responses demonstrates the differences between in the manner that these groups respond to *Brucella* protein epitopes. Interestingly, some of the epitopes mentioned previously (i.e., Bp 26) produced a strong antibody response by Peruvian brucellosis patients, who were culture positive or culture negative patients/Rose Bengal positive patients. These antibody responses could reflect the substantial differences, which these protein epitopes have on the immune system activation, and a large number of antigens recognized by brucellosis patients were identified which have yet to be studied or have limited understanding of their function.

###### 

**Serodiagnostic antigens for culture+ and culture-/Rose Bengal+ vs. Peruvian Naive**.

  Locus Tag/Acc\#/Ch\#; gene position   Function                                                                             Protein mass (kDa)
  ------------------------------------- ------------------------------------------------------------------------------------ --------------------
  BMEI0536                              Periplasmic immunogenic protein (bp26)                                               26,552
  LPS-BM-0.1                            LPS                                                                                  None
  BMEII1048                             60 kDa chaperonin                                                                    57,462
  BMEI0805                              Putative uncharacterized protein                                                     11,217
  BMEII0032                             Type IV secretion system protein; VirB8                                              26,446
  BMEI1330                              Probable serine protease do-like                                                     53,514
  BMEI0855                              Pyruvate dehydrogenase e1 component, β-subunit                                       48,954
  BMEI0228                              *Lema* protein                                                                       23,260
  BMEI0340                              Outer membrane lipoprotein omp16                                                     18,233
  BMEI1890                              Transporter                                                                          34,705
  BMEI1077                              Immunogenic membrane protein yajC                                                    12,560
  BMEII0017                             Outer membrane lipoprotein omp10                                                     13,260
  BMEI0324                              Chemotaxis motb protein                                                              38,302
  BMEI0856                              Dihydrolipoamide acetyltransferase component of PyDH complex                         46,721
  BMEI1980                              DNA protection during starvation protein                                             19,903
  BMEI0141                              Dihydrolipoamide succinyltransferase                                                 42,911
  BMEI0135                              Outer membrane lipoprotein omp19                                                     17,604
  BMEI1060                              Outer membrane protein                                                               27,290
  BMEI0786                              Outer membrane protein (integral)                                                    24,423
  BMEI0587                              Competence lipoprotein                                                               34,770
  BMEII0497                             Enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase/3-hydroxybutyryl-CoA epimerase   80,197
  BMEI1185                              K(+)-insensitive pyrophosphate-energized proton pump                                 73,341
  BMEII0073                             Putative uncharacterized protein                                                     11,277
  BMEI0973                              Putative uncharacterized protein                                                     16,613
  BMEI0962                              Membrane lipoprotein lipid attachment site containing protein                        19,837
  BMEII0589                             6,7-dimethyl-8-ribityllumazine synthase 2 (riboflavin biosynthesis)                  17,356
  BMEII0691                             Putative binding protein                                                             69,388
  BMEI0810                              Putative membrane protein                                                            29,529
  BMEI0339                              Acetyl-coenzyme A carboxylase carboxyl transferase subunit alpha                     35,013
  BMEI0368                              Putative uncharacterized protein                                                     12,741
  BMEII0704                             Bacterioferritin                                                                     18,659
  BMEI0830                              Outer membrane protein                                                               85,919
  BMEII1015                             Sensor protein (kinase transferase)                                                  48,811
  BMEI0503                              Acyl-CoA hydrolase                                                                   14,555

###### 

**Cross-reactive antigens for culture+ or culture-/Rose Bengal+ vs. Peruvian Naïve (negative controls)**.

  Locus Tag/Acc\#/Ch\#; gene position   Function                                                     Protein mass (kDa)
  ------------------------------------- ------------------------------------------------------------ --------------------
  BMEI1079                              Putative outer membrane lipoprotein                          43,604
  BMEI1082                              Seryl-tRNA(Ser/Sec) synthetase                               47,520
  BMEI1084                              Sec-independent protein translocase protein tatA/E homolog   7,999
  BMEII0010                             Hypothetical membrane associated protein                     67,136
  BMEI1033                              Putative uncharacterized protein                             23,107
  BMEII0917                             Putative uncharacterized protein                             17,923
  BMEII1111                             Putative uncharacterized protein                             16,629
  BMEII0040                             Glutamate synthase (large chain)                             173,600
  BMEII0356                             Galactonate dehydratase                                      66,751
  BMEI1382                              Betaine aldehyde dehydrogenase                               52,035

###### 

**Serodiagnostic antigens for culture+ vs. culture-/Rose Bengal+**.

  Locus Tag/Acc\#/Ch\#; gene position   Function                                   Protein mass (kDa)
  ------------------------------------- ------------------------------------------ --------------------
  BMEII0173                             Putative uncharacterized protein           11,277
  BMEII0029                             Type IV secretion system protein virB5     26,810
  BMEII0182                             Putative uncharacterized protein           8,718
  BMEII0054                             Putative uncharacterized protein           5,237
  BMEII1049                             Putative uncharacterized protein           7,955
  BMEII0558                             Putative uncharacterized protein           7,596
  BMEII0532                             Hypothetical membrane associated protein   7,916
  BMEII0892                             Putative uncharacterized protein           6,762
  BMEI1502                              Alkaline phosphatase like protein          21,488
  BMEII0720                             Transcriptional regulator                  7,304

There could be a potential difference in the antibody responses compared to cytokine release assays for these specific epitopes, which produced antibody responses. Based on unpublished data, Bp26, which gave a strong antibody response, does not give a strong TH~1~ response; VirB8 does generate a strong TH~1~ response, yet does not give a particularly strong antibody response. The use of an epitope database has previously been used for *Mycobacteria tuberculosis*, and other infections by estimating the immune responses to epitopes associated with a certain organism (Blythe et al., [@B4]). A complete cytokine release assay for the entire brucellar proteome has not been undertaken. Based on the fact that antibody production is not protective in chronic brucellosis, we must conclude that T cell assays would be a more appropriate method to pursue with regards to not only diagnostic purposes, but for development of a recombinant protein vaccine as well.

Conclusion
==========

*Brucella* spp. are important intracellular human and animal pathogens associated with fascinating mechanisms of immune modulation and subversion of APCs as an intrinsic mechanism of the diseases that they cause. New systems biology analyses of antigens recognized by human immune responses in brucellosis have identified large numbers of protein antigens with potential for understanding mechanisms of pathogenesis and immune evasion and may point the way toward novel vaccine and diagnostic approaches. These approaches have generalized applicability to the analysis of T cell responses associated chronic bacterial, fungal and parasitic infections other than *Brucella*.
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